[ad_1]
December 16, 2022
Within the largest healthcare merger introduced this yr, S&C is advising biotechnology firm Amgen in its pending acquisition of Horizon Therapeutics for an enterprise worth of $28.3 billion, with the shopper prevailing over competing bids. Horizon Therapeutics is a worldwide biotechnology firm headquartered in Dublin, Eire that develops medicines that deal with vital wants for folks affected by uncommon, autoimmune and extreme inflammatory illnesses.
The cross-border S&C crew advising Amgen consists of Frank Aquila, Miaoting (Mimi) Wu, Spencer Nord and Andrew Kim. The finance crew, which helped safe $28.5 billion in acquisition financing, included Ari Blaut, Presley Warner, Joyce Kwok, Matthew Squire, Hannah Cockle and Dermot Costello. S&C legal professionals from London, New York, Palo Alto, Washington, D.C., Brussels and Frankfurt are advising on Takeover Panel, government compensation, tax, mental property and competitors issues.
S&C has recommended the biotechnology firm for almost 20 years, together with advising on Amgen’s $1.9 billion acquisition of 5 Prime Therapeutics in 2021, its $13.4 billion buy of the worldwide rights to Otezla in 2019, its $9.7 billion acquisition of Onyx Prescription drugs in 2013 and its $2.2 billion buy of Abgenix in 2005.
Our multidisciplinary Healthcare & Life Sciences apply delivers best-in-class providers to purchasers of all sizes, from start-ups to funding funds to the biggest international healthcare companies. We now have suggested on a number of the largest current offers on this sphere, together with Abiomed’s $18 billion pending acquisition by J&J, Biohaven Pharmaceuticals’ $11.6 billion acquisition by Pfizer, Baxter International’s $12.4 billion acquisition of Hillrom, and Haleon’s demerger from GSK and landmark European itemizing creating the world’s greatest stand-alone shopper well being firm.
Latest Podcasts and Movies
Subscribe to remain updated on developments in M&A and Healthcare & Life Sciences.
[ad_2]
Source link